Research Analysts Offer Predictions for PBYI Q4 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Research analysts at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for Puma Biotechnology in a research report issued on Wednesday, January 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.16 per share for the quarter, up from their prior forecast of $0.13. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Several other equities analysts have also recently issued reports on PBYI. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Friday, December 6th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI traded down $0.03 during trading on Friday, hitting $3.00. 128,537 shares of the company were exchanged, compared to its average volume of 835,815. Puma Biotechnology has a 1-year low of $2.22 and a 1-year high of $7.73. The company has a market capitalization of $147.02 million, a P/E ratio of 6.24 and a beta of 1.10. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business's 50 day moving average is $3.05 and its 200-day moving average is $2.99.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to analysts' expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the previous year, the business posted $0.12 earnings per share.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors have recently bought and sold shares of PBYI. Patriot Financial Group Insurance Agency LLC increased its position in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 8,000 shares during the last quarter. Royce & Associates LP lifted its stake in shares of Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 8,427 shares in the last quarter. Gateway Wealth Partners LLC bought a new position in shares of Puma Biotechnology in the fourth quarter worth $31,000. Squarepoint Ops LLC boosted its stake in Puma Biotechnology by 17.7% in the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company's stock worth $233,000 after purchasing an additional 10,757 shares during the period. Finally, SG Americas Securities LLC grew its stake in Puma Biotechnology by 83.9% during the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 11,252 shares in the last quarter. Institutional investors own 61.29% of the company's stock.

Insiders Place Their Bets

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by corporate insiders.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.